PD-L1 expression testing in lung carcinoma prior to pembrolizumab therapy (Dako PD-L1 IHC 22C3 PharmDX kit)
PD-L1 is an immune-related biomarker that can be expressed on tumour cells.
Evaluating PD-L1 expression level at diagnosis of NSCLC contributes to a better understanding of your patient’s tumour and helps inform treatment decisions.
Lab 21 is currently offering a service based on the Dako PD-L1 22C3 pharmDx kit, it is a qualitative assay for use in the detection of PD-L1 in formalin fixed, paraffin-embedded (FFPE) in non – small cell lung carcinoma.
To request PD-L1 testing, please contact the Lab 21 Customer Services Team for further information regarding requesting the test and pricing.
Not provided under our UKAS accreditation.
Please see our Accreditation page for full scope of accredited testing.